Summary of the workshop "The Pre-Clinical Safety Evaluation of Biotechnology : Derived Pharmaceuticals"(WORKSHOP 1 : THE WAY TOXICITY EVALUATIONS OF BIO-PHARMACEUTICAL PRODUCTS SHOULD BE CONDUCTED (TOXICOLOGICAL QUESTIONS & ANSWERS-ISSUE 2002).ICH-S6)

スポンサーリンク

概要

• 論文の詳細を見る
• 日本トキシコロジー学会の論文

著者

• Kadota Toshihito

  Nippon Boehringer Ingelheim Co. Ltd.

• WATABE Tadashi

  Toyama Medical & Pharmaceutical Univ.

関連論文

• Question and Answer on Toxicity 2003 : How far have methods for toxicity assessment been harmonized? (WORKSHOP4: QUESTION AND ANSWER ON TOXICITY 2003; HOW FAR HAVE METHODS FOR TOXICITY ASSESSMENT BEEN HARMONIZED?) (Proceedings of the 30th Annual Meeting)
• Organizers' introduction(WORKSHOP 1 : THE WAY TOXICITY EVALUATIONS OF BIO-PHARMACEUTICAL PRODUCTS SHOULD BE CONDUCTED (TOXICOLOGICAL QUESTIONS & ANSWERS-ISSUE 2002).ICH-S6)
• S11-1 Toxicology on Regulatory Sciences ; Interpretation of Definition and Signiflcance of NOAEL (No Observed Adverse Effect Level) for Pharmaceuticals(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE
• S11-5 "5. Q&A and Discussion"(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE OF NOAEL (NON-OBSERVED ADVERSE EFFECT LEVEL) FOR PHARMACEUTICALS)(Proceedings of the 31st Annual Meeting)
• Summary of the workshop "The Pre-Clinical Safety Evaluation of Biotechnology : Derived Pharmaceuticals"(WORKSHOP 1 : THE WAY TOXICITY EVALUATIONS OF BIO-PHARMACEUTICAL PRODUCTS SHOULD BE CONDUCTED (TOXICOLOGICAL QUESTIONS & ANSWERS-ISSUE 2002).ICH-S6)

スポンサーリンク